Last reviewed · How we verify
ALISPORIVIR
Alisporivir is an experimental hepatitis C drug tested in small Phase 2 trials for patients with chronic HCV infection.
Alisporivir is an investigational antiviral targeting hepatitis C virus (HCV) replication. It was studied in Phase 2 trials for chronic HCV genotype infections, often in combination with ribavirin or pegylated interferon. A key differentiator is its evaluation in patients who cannot tolerate interferon-based regimens.
At a glance
| Generic name | ALISPORIVIR |
|---|---|
| Modality | Recombinant protein |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Mechanism of action
Alisporivir is being studied as a treatment for chronic hepatitis C virus infection. It works by targeting the virus's ability to replicate inside liver cells. The drug has been tested in people with different hepatitis C genotypes, often alongside other antiviral medications like ribavirin or pegylated interferon. Researchers are particularly interested in using it for patients who cannot take interferon-based treatments due to side effects or other health reasons.
Approved indications
Common side effects
Key clinical trials
- A Multicenter, Randomized, Open Label, Parallel-group Phase IIB Study on the Efficacy and Safety of Oral Regimens of DEB025 Alone or in Combination With Ribavirin Versus Standard of Care (Peg-IFNα2a P (Phase 2)
- A Multicenter, Single-arm Trial Evaluating the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-IFNα2a/RBV) in Protease Inhibitor Treatment Fai (Phase 3)
- A Multicenter, Open-label, Randomized, 2-arm, Phase II Trial of Pharmacodynamics, Pharmacokinetics and Safety of Two Dose Regimens of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chroni (Phase 2)
- An Open-label, Two Part Investigation of the Pharmacokinetics, Safety, and Tolerability of Alisporivir and EDP239 When Co-administered to Healthy Adult Subjects (Phase 1)
- A Multi-centre Long Term Follow-up Study to Assess the Durability of Sustained Virologic Response in Alisporivir-treated Chronic Hepatitis C Patients (Phase 3)
- A Randomized, Open Label Trial of the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-INFα2a/RBV) and Boceprevir in Combination With Peg-INFα2 (Phase 3)
- Evaluation of the Efficacy, Safety and Tolerability of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19). A Randomised, Open-label, Proof of Concept, (Phase 2)
- An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Single Oral Doses of DEB025 in Subjects With Mild and Moderate Hepatic Impairment Compared to Matched Healthy Subjects (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALISPORIVIR CI brief — competitive landscape report
- ALISPORIVIR updates RSS · CI watch RSS
- portfolio CI